Madrigal Pharmaceuticals, Inc.

NasdaqGS MDGL

Madrigal Pharmaceuticals, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 77.06

Madrigal Pharmaceuticals, Inc. Price to Sales Ratio (P/S) is 77.06 on January 14, 2025, a -98.77% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Madrigal Pharmaceuticals, Inc. 52-week high Price to Sales Ratio (P/S) is 7,607.24 on June 11, 2024, which is 9,771.64% above the current Price to Sales Ratio (P/S).
Madrigal Pharmaceuticals, Inc. 52-week low Price to Sales Ratio (P/S) is 56.02 on October 23, 2024, which is -27.30% below the current Price to Sales Ratio (P/S).
Madrigal Pharmaceuticals, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2,933.59.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: MDGL

Madrigal Pharmaceuticals, Inc.

CEO	Mr. William J. Sibold
IPO Date	Feb. 6, 2007
Location	United States
Headquarters	Four Tower Bridge
Employees	376
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Key trends

Past 5 years